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Abstract
Background: Geographic Information Systems (GIS) combined with spatial analytical methods could be helpful in
examining patterns of drug use. Little attention has been paid to geographic variation of cardiovascular
prescription use in Taiwan. The main objective was to use local spatial association statistics to test whether or not
the cardiovascular medication-prescribing pattern is homogenous across 352 townships in Taiwan.
Methods: The statistical methods used were the global measures of Moran’s I and Local Indicators of Spatial
Association (LISA). While Moran’s I provides information on the overall spatial distribution of the data, LISA provides
information on types of spatial association at the local level. LISA statistics can also be used to identify influential
locations in spatial association analysis. The major classes of prescription cardiovascular drugs were taken from
Taiwan’s National Health Insurance Research Database (NHIRD), which has a coverage rate of over 97%. The dosage
of each prescription was converted into defined daily doses to measure the consumption of each class of drugs.
Data were analyzed with ArcGIS and GeoDa at the township level.
Results: The LISA statistics showed an unusual use of cardiovascular medications in the southern townships with
high local variation. Patterns of drug use also showed more low-low spatial clusters (cold spots) than high-high
spatial clusters (hot spots), and those low-low associations were clustered in the rural areas.
Conclusions: The cardiovascular drug prescribing patterns were heterogeneous across Taiwan. In particular, a clear
pattern of north-south disparity exists. Such spatial clustering helps prioritize the target areas that require better
education concerning drug use.
Background
Spatial analysis can identify inequities in disease distri-
bution or in resources for healthcare utilization, result-
ing in financial incentives in payment policies [1-3].
Spatial analysis has taken giant steps forward in the
recent decade, and Geographic Information Systems
(GIS) software makes it possible to undertake a sophisti-
cated visual approach to data analysis in medical issues
[4,5]. However, most studies using GIS have relied on
their mapping capabilities rather than performance of
statistical analyses [6-8]. Only when GIS are combined
with spatial analytical methods can the result provide a
helpful tool in the study of public health issues [9,10].
Spatial analyses can be compared to societal norms or
objectives. The traditional descriptive statistics fail to
show the complexity of interactions between individual
geographic units. In contrast, spatial analysis can reveal
the co-variation of properties with a geo-space, since
characteristics at proximal locations tend to be corre-
lated, either positively or negatively, which leads to spa-
tial autocorrelation [11]. For example, a study shows
that people are indirectly protected when more people
in their neighborhood are vaccinated with cholera vac-
cine [12].
Another potential use of the spatial analysis is to
examine patterns of drug use. Spatial analysis provides a
method for delineating the complex nature of the asso-
ciations between multiple levels of social structure and
illicit drug use [13,14]. These applications have impor-
tant implications in policy-making, as the associations
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planning drug prevention programs.
Cardiovascular disease (CVD) remains the leading
cause of death and disability, representing a major bur-
den for health systems worldwide [15,16], and impress-
ive literature has documented geographic variation in
the use of medication and procedures for treating car-
diovascular disease in Western countries [17-21]. The
cardiovascular medication-use patterns observed reflect
the influence of a complex combination of demo-
graphic, social, economic, cultural, and environmental
factors. Quality improvement programs based on geo-
graphic data may help to reduce the variation in qual-
i t yo fc a r e[ 2 2 ] .
A few previous studies have specifically examined the
cardiovascular medication utilization in Taiwan [23,24];
however, seldom is the spatial pattern of drug use
addressed. Therefore, the objective of this study was to
investigate prescribing patterns of cardiovascular medi-
cations based on the variations of geo-space in Taiwan.
We hypothesized there would be significant geographic
differences in prescribing cardiovascular medications
among townships.
Methods
Data source
We conducted a cross-sectional study by using the non-
sampled National Health Insurance Research Database
(NHIRD) in Taiwan. This database is population-based
and derived from the claims data of the National Health
Insurance program, a mandatory-enrollment and single-
payer system implemented in 1995 [25]. Patients who
had at least one outpatient prescription for CVD during
the year 2004 were enrolled in this study. The dataset
contained 22.13 million enrollees (about 97.5% of the
total population in Taiwan) in 2004.
The data elements available for each patient in
NHIRD contains minimal demographic characteristics,
medical diagnoses (up to 5 for each admission, up to 3
for each ambulatory visit), procedures, expenditures, and
all detailed prescriptions [26].
Cardiovascular medications
The prescriptions were coded according to the Anato-
mical Therapeutic Chemical coding system of the NHI
Pharmaceutical subsidy, which was used as the interface
for retrieving the pharmaceutical claims data. Five drug
classes (and ATC numbers) were recorded, including
agents acting on the rennin-angiotensin system (C09),
called Group A hereafter; beta blocking agents (C07),
called Group B hereafter; calcium channel blockers
(C08), called Group C hereafter; diuretics (C03), called
Group D hereafter; and antihypertensives (C02), called
Group O hereafter. We presented the proportion of use
of these cardiovascular drug classes among all patients
based on geographic location. We used the “defined
daily dose” (DDD) as a measure unit for drug consump-
tion, which was developed by the World Health Organi-
zation (WHO) Collaborating Center for Drug Statistics
Methodology (WHO, 2004). The DDD of a pharmaceu-
tical substance represents the assumed average mainte-
n a n c ed o s ep e rd a yf o rad r u g ,w h e nu s e df o ri t sm a i n
indication in adults. For example, the recommended
maintenance dose of captopril, an angiotensin convert-
ing enzyme inhibitor, for hypertension is 50 mg to 75
mg per day, the DDD of this drug was define as 50 mg
from WHO. The consumption of drugs was expressed
as DDDs/1000 inhabitants per day, which may serve as
an estimation of the proportion of the population
receiving the drug treatment. The information on resi-
dents in each township in Taiwan was based on annual
statistics of the Ministry of Interior [27].
Geographic distribution
Taiwan became one of East Asia’s economic “Tigers” in
the twentieth century. Its population was more than 22
million in the year 2000, with a combined area of
approximately 36,000 square kilometers. The study area
focuses on the main island of Taiwan; the offshore
islands are not considered. In total, there are 352 town-
ships included in this study, which can be further classi-
fied into 5 metropolitan areas, 2 secondary metropolitan
areas, 206 rural townships, and 55 aboriginal townships
(Figure 1)[28]. The metropolitan classification was
revised in 1993 by the Directorate General of Budget,
Accounting, and Statistics of Taiwan. According to this
classification, there are 5 major metropolitan areas (Tai-
pei-Keelung, Taoyuan-Chungli, Taichung-Changhwa,
Tainan, and Kaohsiung) and 2 secondary metropolitan
areas (Hsinchu and Chiayi), which consist of 66.87% of
the population. Each metropolitan area usually has at
least one core city with satellite cities of similar socio-
economic attributes. A metropolitan area has at least 0.3
million people, with population above 1 million consid-
ered a major metropolitan area and below 1 million a
secondary metropolitan area. The Council of Indigenous
Peoples of Taiwan defines 55 aboriginal townships,
including 30 indigenous mountain and 25 plain town-
ships. Although Taiwan has experienced rapid economic
growth, there has been a south-north (using Taichung-
Changhwa as the division) inequity. That is, the region
north of the Taichung-Changhwa area has a more
highly developed service economy, technology complex,
and financial sector than the southern region.
Statistical Analysis
We analyzed consumption of all classes of cardiovascu-
lar medications by DDD/1000 inhabitants per day across
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drug consumption by metropolitan areas, including the
mean (± standard deviation). Coefficient of variation
(COV, standard deviation divided by mean) is used to
describe the variations of consumption in various areas.
Bivariate analysis using the Student’sttest was con-
ducted to compare the south and north regions of Tai-
wan; a two-sided p value < 0.05 was considered
statistically significant. Data were extracted from
NHIRD, and descriptive analysis were performed with
SAS version 9.1 (SAS Institute Inc., Cary, North
Carolina)
Local Indicators of Spatial Association (LISA) [29]
allows us to decompose the study area into small loca-
tions, thus enabling the assessment of significant local
spatial clustering around an individual location. In addi-
tion to the degree of spatial clustering, the detailed var-
iations of clustering in the locally defined geo-space are
identified as well as the locations of the spatial clusters.
The local version of Moran’s I at location i is given by:
Ii =
(xi − ¯ x)
1
n

i
(xi − ¯ x)
2

j
wij(xj − ¯ x)
where n indicates the total number of locations (352
townships), xi denotes the value of the variable of inter-
est, X, at location i, xj denotes the observation at neigh-
boring locations j,a n d¯ x i st h es a m p l ea v e r a g eo fX. wij
is the so-called spatial weights matrix (connectivity
matrix), which defines spatial interaction across study
regions. In general, wij = 1 if location i and location j
are neighboring, (share a common boundary); otherwise,
wij = 0. In the LISA analysis, if the test statistic is not
significant at any sensible level, no spatial pattern is
present in the areas; i.e., observations are spatially ran-
dom. When it is significant, however, two possible pat-
terns of local spatial clusters are likely to be exhibited:
(1) When xi is higher than the average of the entire
s t u d ya r e a( ¯ x) and so are its neighbors, a high-high
(HH) association, a so-called hot spot, is indicated. (2)
When both xi and its neighbors are lower than the
average, the spatial tendency is low-low (LL), or a cold
spot. The major limitation of Moran’s I is that it only
measures spatial clustering (spatial autocorrelation) at a
global scale, but cannot detect important clusters at a
local scale and determine the spatial patterns for the
specific locations. To make spatial autocorrelation
visually meaningful, the local Moran I is represented by
cluster maps, in which the locations of significant spa-
tial clusters are highlighted to identify the patterns of
associations and p value < 0.01 was considered statisti-
cally significant.
Underlying spatial clusters can be geographic changes
in risk factors, which introduce a degree of spatial auto-
correlation in the outcome. In this study, spatial clusters
of drug use reflect inefficiency in medical resources and
utilization. Still, a variety of possible factors could lead
to such inefficiency and they are location-specific. How-
ever, if there exist common factors creating diffusion or
local clusters of medical inefficiency, it would be helpful
and necessary to identify the locations of risk clusters
and the extent of their clustering. Based on the sizes of
risk areas and the significance of clusters, important risk
factors shared by neighboring areas could be uncovered.
Thus, from the perspective of policy making and
research, priority should beg i v e nt ot h e s ec l u s t e r e d
areas.
We used the geographic information system software
ArcGIS v9.2 to combine drug prescription data with
Taiwan digital maps at the township level. The data was
then processed by spatial analysis software GeoDa [30]
to create the spatial weights matrix and to calculate the
LISA value for each township.
Figure 1 Map of metropolitan areas and aboriginal townships
in Taiwan. The map of the study region in Taiwan includes 7
metropolitan areas and the area of 55 aboriginal townships.
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Geographic map and geographic distribution of drugs
consumption
Figure 1 illustrates the administrative division across 352
townships in Taiwan, including 5 major metropolitan
areas, 2 secondary metropolitan areas, 206 rural areas,
and 55 aboriginal townships.
The pattern of drug consumption across townships
indicated the highest utilization was of Group C fol-
l o w e db yG r o u pA ,G r o u pB ,G r o u pD ,a n dG r o u pO .
(Table 1) Among all groups of drugs, variations in con-
sumption by metropolitan areas were the largest in
Hsinchu (COV = 100 to 119%), followed by Tainan
(COV = 71 to 106%), rural township (COV = 55 to
102%) and aboriginal area (COV = 38 to 98%).
We did not observe any significant difference in cardi-
ovascular medication consumption between northern
and southern areas: Group A (21.2 ± 33.6, 17.8 ± 40.5;
p = 0.67), Group B (11.8 ± 17.2, 10.1 ± 17.5; p = 0.51),
Group C (20.8 ± 34.9, 19.0 ± 38.3; p = 0.86), Group D
(6.3 ± 10.9, 5.6 ± 13.5; p = 0.83) and Group O (1.5 ±
3.1, 1.5 ± 3.4; p = 0.70), respectively.
LISA statistics for cardiovascular drugs
Figure 2 displays plots of the LISA statistics for each
class of cardiovascular drug utilization. The marked
polygons indicated areas with significant spatial cluster-
ing, while the blank polygons indicated areas with insig-
nificant spatial clustering.
There were wide variations in utilization of all drug
classes across the 352 townships in Taiwan. From the
first glimpse of the LISA figures, under-utilization
appeared to be the predominant spatial pattern for car-
diovascular disorders across all drug classes: the total
number of high-high associations (hot spots) amounts
to 35, while low-low associations (cold spots) reaches to
85. Such spatial variations carried three statistical mean-
ings: (1) variations were non-random; (2) variations
were statistically significant; (3) variations exhibited
effects of neighboring interactions.
North-south discrepancy distribution
Focusing on the west of Taiwan, where more than 97
percent of the population resides, patterns of drug use
exhibited more high-high associations clustered in the
southern (n = 30) than northern (n = 2) townships.
Thus the southern region had higher-than-average utili-
zation of cardiovascular drugs than other parts of Tai-
wan. However, at the same time, the number of low-low
associations also presented in southern (n = 42) more
than northern areas (n = 33).
Tables 2 summarizes the distribution of spatial asso-
ciations for each drug class by the levels of urbanization.
Among all drug classes, a large number of significant
LISA statistics were observed in metropolitan areas fol-
lowed by aboriginal, rural, and secondary metropolitan
areas. Among those metropolitan areas, the significant
LISA statistics were mostly observed in the southern
townships such as Kaohsiung and Tainan city. In other
words, with each prescription drug, more observations
were correlated with their neighboring values, giving evi-
dence of possible diffusion effects of drug use.
By drug class, both Group C and Group D had the
highest amount of diverse clusters across the country,
followed by Group B, Group A, and Group O. Hot spot
areas concentrated mostly in the Kaohsiung and rural
areas among all drug classes (Table 2). In contrast, cold
spot areas showed up in rural and aboriginal townships
areas, accounting for a particularly high portion of
g r o u pA ,f o l l o w e db yg r o u pB ,g r o u pC ,g r o u pO ,a n d
group D.
Discussion
Our study showed a variability of cardiovascular pre-
scription patterns with regard to geographic differences
in Taiwan. The analysis of both HH and LL associations
Table 1 The distribution of cardiovascular medications consumption by urbanicity, data presented as mean ± (SD)
a
Population (%) Group A
b Group B Group C Group D Group O
Taipei-Keelung metropolitan area (N = 44) 6,609,220 (29.4) 32.2 (42.0) 18.1 (22.1) 32.3 (43.4) 10.2 (12.8) 2.7 (4.7)
Taoyuan-Chungli metropolitan area (N = 12) 1,846,082 (8.2) 40.9 (79.5) 20.0 (34.9) 40.4 (72.0) 11.7 (23.9) 2.4 (2.8)
Hsinchu secondary metropolitan Area (N = 10) 682,132 (3.0) 18.2 (15.9) 11.0 (9.2) 21.2 (18.4) 6.1 (5.7) 1.1 (1.1)
Taichung-Changhwa metropolitan area (N = 18) 2,092,344 (9.3) 41.7 (60.3) 24.1 (33.2) 45.6 (71.5) 13.5 (20.6) 3.5 (4.4)
Chiayi secondary metropolitan area (N = 4) 373,774 (1.7) 36.5 (42.8) 19.5 (19.6) 40.1 (49.5) 13.1 (17.6) 4.3 (5.9)
Tainan metropolitan area (N = 14) 1,246,084 (5.5) 27.1 (26.7) 15.6 (14.6) 31.7 (32.9) 7.2 (7.4) 2.7 (3.8)
Kaohsiung metropolitan area (N = 28) 2,758,140 (12.2) 43.9 (94.0) 23.0 (37.8) 45.7 (82.5) 12.5 (24.6) 3.7 (4.5)
Rural townships area (N = 167) 6,100,872 (27.1) 18.2 (18.2) 10.7 (10.4) 19.3 (21.1) 5.7 (7.8) 1.6 (2.9)
Aboriginal townships area (N = 55) 812,703 (3.6) 25.3 (26.5) 10.4 (10.6) 19.6 (22.7) 7.7 (9.5) 1.3 (3.4)
Total (N = 352) 22,521,351 (100) 25.7 (40.8) 13.9 (19.1) 26.0 (40.3) 7.9 (12.7) 2.1 (3.6)
a. Data presented as DDD/1000 inhabitants per day
b. Group A, agents acting on the rennin-angiotensin system; Group B, beta blocking agents; Group C, calcium channel blockers; Group D, diuretics; Group O,
antihypertensives
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Group A
d Group B Group C Group D Group O
H
a L
b HLHLHL H L
Taipei-Keelung metropolitan area (N = 44) 1 (2.3) 4 (9.1) 0 (0.0) 2 (4.5) 0 (0.0) 4 (9.1) 1 (2.3) 3 (6.8) 0 (0.0) 5 (11.4)
Hsinchu secondary metropolitan Area (N = 10) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (10.0) 0 (0.0) 3 (30.0) 0 (0.0) 0 (0.0)
Tainan metropolitan area (N = 14) 0 (0.0) 0 (0.0) 0 (0.0) 2 (14.3) 0 (0.0) 0 (0.0) 0 (0.0) 2 (14.3) 0 (0.0) 0 (0.0)
Kaohsiung metropolitan area (N = 28) 2 (7.1) 1 (3.6) 3 (10.7) 2 (7.1) 4(14.3) 3 (10.7) 4 (14.3) 1 (3.6) 2(7.1) 1 (3.6)
Rural townships area (N = 167) 3 (1.7) 7 (4.0) 3 (1.7) 7 (4.0) 4 (2.3) 6 (3.5) 2 (1.2) 6 (3.5) 1 (0.6) 6 (3.5)
Aboriginal townships area (N = 55) 0 (0.0) 5 (9.1) 1 (1.8) 4 (7.3) 1 (1.8) 4 (7.3) 2 (3.6) 2 (3.6) 1 (1.8) 4 (7.3)
Total (N = 352)
c 6 (1.7) 17 (4.8) 7 (2.0) 17 (4.8) 9 (2.6) 18 (5.1) 9 (2.6) 17 (4.8) 4 (1.1) 16 (4.5)
a. High-high association (hot spot), meanings utilization was higher than average
b. Low-low association (cold spot), meanings utilization was lower than average
c. Three areas did not presented any hot spot or cold spot including Taichung-Changhwa metropolitan, Chungli-Taoyuan metropolitan, and Chiayi secondary
metropolitan areas.
d. Group A, agents acting on the rennin-angiotensin system; Group B, beta blocking agents; Group C, calcium channel blockers; Group D, diuretics; Group O,
antihypertensives
Figure 2 Spatial clusters of cardiovascular drugs in Taiwan. A high-high association of the LISA statistics indicates the location is higher than
the average of the entire study area and so are its neighbors, or a hot spot; a low-low association indicates both the location and its neighbors
are lower than the average, or a cold spot.
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use between the north and the south of Taiwan, and the
southern areas exhibited spatial clustering of unusual
utilization in cardiovascular drugs. There are two possi-
ble explanations for this finding. First, the disease preva-
lence may be different between the north and south in
Taiwan as a result of urbanization levels. The prevalence
of cardiovascular disease, such as hypertension and cor-
onary heart disease, varies between the urban and rural
areas. Some countries reported the prevalence was
h i g h e rf o rp e o p l el i v i n gi nt h eu r b a nt h a nr u r a la r e a s
[31,32], while others, including Taiwan, presented evi-
dence to the contrary [33,34]. Second, there were
urban-rural differences in the appropriateness of disease
treatment and the inclination of patients to receive med-
ical care. Previous studies have documented regional
variation in quality of care in cardiovascular disease
[22,35]. Patients hospitalized for acute myocardial
infarction (AMI) in rural hospitals were less likely to
receive recommended intervention than in urban hospi-
tals. In addition, inappropriate or lower utilization of
health care could be associated with lower socioeco-
nomic status of patients in rural areas [36,37].
Utilization of cardiovascular drugs appeared to be
associated with different classes of pharmacological
drugs among geographic regions. We found that under-
utilization of all classes of drugs was more likely to be
observed than overutilization, and the former was scat-
tered mainly in the southern, rural, and aboriginal town-
ships. (Figure 2) It seemed to suggest a wide variation in
prescribing behavior. Drug Group A, Group B, and
Group C were generally the most widely used drugs for
the treatment of cardiovascular diseases [38]; however,
there were large variations across townships with regard
to the use of drugs. A study conducted in France
reported the socio-economic status at the area level
influenced the utilization of specialty care [39]. Differ-
ences between general practitioners and other specialties
have been described in relation to the use of cardiovas-
cular medicines [40-42]. For example, compared with
cardiologists, family practitioners and general internists
probably underutilize ACE inhibitors due to less knowl-
edge about heart failure and poor adherence to guide-
lines [42]. Among seventeen townships where ACE
inhibitors were underutilized, we found that a clinic for
primary care is the major medical resource in these
areas [43]. In addition, there are three aboriginal town-
ships have the High-High hotspot. They tend to over-
utilize Group B, C, D and O but not ACEI inhibitors.
This might be attributable to the fact that the aboriginal
residents only have access to general practitioners and
medical treatment by specialists is lacking. Accordingly,
the spatial patterns of drug use observed in this study
suggested that there was a wide variation in physicians’
prescribing behavior across Taiwan, to the extent that
medical resources were not consistently utilized among
352 townships.
Utilization of cardiovascular drugs also associated with
the disease patterns appeared to be different between
townships. Some studies showed that rural residents are
at higher risk for the burden of major diseases such as
cardiovascular disorder and the severity of their compli-
cations [33,44]. In contrast, other studies showed that
higher prevalence rates of cardiovascular risk factors
were found in urban than rural areas due to diet and
stressful life styles [31,45]. Drug choice should be based
on clinical features of patients. For instance, rennin-
angiotensin system agents have greatly improved clinical
outcomes in patients with renal complications, [46] or
diuretics are first-line agents for elderly hypertensive
patients without other complications [47].
Spatial analytical methods recognize that spatial con-
cordance between two proximal entities is closely con-
nected by intrinsic causal relationship or hidden
confounders. Although the geographical variations in
drug use were widely documented, the concept of spatial
dependence has received little attention in pharmacoepi-
demiology. It was our intention in this study to establish
that “spatial perspectives in pharmacoepidemiology”
would be an effective method in detecting the variation
of drug utilization. That is, unusual drug prescriptions
are not randomly located across locations but tend to be
concentrated within certain areas.
LISAs are simply local derivations or disaggregation of
global measures of spatial autocorrelation, and allow
one to detail the information of local variations in spa-
tial autocorrelation (e.g., hot spots and cold spots) for
further study consideration[48]. This method is useful
to indicate spatial correlation of similar values at loca-
tion i and its neighborhood. This means that location i
and its neighborhood can both have values above the
average value (hot spots), or both can have values below
the average (cold spots). Such local variations in spatial
autocorrelation are statistically significant. Departure
from the classical assumption of statistical indepen-
dence, the spatial clusters represent that data are not
randomly distributed over the global region and can
occur because there is a contagious factor to the under-
lying process that is commonly shared by the clustered
region. Lack of the factor that triggers spatial depen-
dence does not give rise to spatial clustering.
The primary strength of this study was that we incor-
porated GIS and tools for spatial analysis to explore the
role of geography in drug utilization. In so doing, we
were able to divert our examination from the traditional
framework, which only considers individual decision-
making, into the spatial realm. Epidemiologic investiga-
tions are commonly involved with data from contiguous
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tions may share similar prescribing patterns due to, for
example, inhabitants’ lifestyle behaviors or environmen-
tal exposures. Although the trend in utilization of cardi-
ovascular drugs in Taiwan was investigated, little was
known regarding its geographical pattern across town-
ships. The spatial analysis presented here may add
essential information to pharmacoepidemiological stu-
dies and policy-making. On the one hand, spatial analy-
sis allows us to examine spatial processes underlying the
prescribing behavior of physicians and provides the first
inquiry into whether spatial components should be
accounted for in modeling to avoid erroneous inference
[49]. On the other hand, given the limited resources, the
government can focus their policy efforts to target areas
to improve drug utilization. For the reasons described
above, our approach should be applicable worldwide.
Developing countries, for which medical resources are
increasingly disproportionately distributed, may see
more distinct prescribing patterns than those for Taiwan
or other developed countries.
Although spatial analysis with Moran’s I is useful for
this study, it does have limitations of which all should
be aware. First, Moran’s I (and other global indicators)
is not powerful enough to differentiate well between a
random pattern and a pattern without substantial spatial
variations. Second, Moran’s I is conditional, tied to how
we define localities through a spatial weights matrix wij.
Different definitions of the matrix can lead to different
values of spatial dependence. Finally, the measures of
spatial dependence are subject to the modifiable areal
unit problem. The problem arises due to the arbitrary
choice and the modifiable nature of areal units in spatial
analysis, in the sense that they can be aggregated to
form units of different sizes of spatial arrangements.
The degree of spatial association, as measured by Mor-
an’s I, changes with different levels of aggregation in
areal units. While we are aware of the limitations of the
spatial autocorrelation index, our results in this paper
can be interpreted as a broad indication of the presence
and magnitude of spatial dependence.
Other potential limitations of our study also should be
noted. First, the utilization pattern of cardiovascular
medications could be different as urbanization changes.
Second, we only analyzed the classes of cardiovascular
drugs based on the first three digits of ATC which have
D D Da s s i g n e d .A l t h o u g hw ew e r ea b l et od e p i c tt h e
spatial patterns of drug use, whether the knowledge of
new drugs was attributable to the geographic clustering
requires a detailed classification of drug classes based
on ATC. Third, we might underestimate the utilization
o fg r o u pA ,B ,Db e c a u s ec o m p lex medication (i.e., a
compound made of two or more ingredients) without
DDD assigned were not estimated in this study. The
most complex medication are combinations with group
D (i.e., group A plus group D or group B plus group D)
to improve patient’s compliance. Fourth, this study only
analyzed one year of data, but the prescribing pattern
could extend across years. Fifth, the cardiovascular med-
ication pattern did not correspond to disease distribu-
tion. Most patients need two more classes of
medication to control their disease, except simple essen-
tial hypertension[47]. Finally, the fact that we have
observed significant spatial autocorrelation in our data
does not determine whether these are true spatial
effects or are spurious in the sense that they can be
attributed entirely to patterns in other variables, such as
income or individual characteristics (such as age, gen-
der, etc). If we control for all of these other factors and
the spatial variable remains significant, then we have
evidence that the patterns are consistent with a neigh-
borhood effect and are not solely attributable to socioe-
conomic characteristics of these areas. Exploring theses
sources of spatial patterns and the mechanisms that
may be driving them is an obvious extension of the ana-
lysis presented here, and more detailed studies are
necessary to better understand the factors that influence
prescribing patterns.
Conclusions
The cardiovascular medication prescribing patterns were
heterogeneous across Taiwan. In particular, a clear pat-
tern of north-south disparity exists. The spatial variabil-
ity of prescribing patterns documented in this study
shows that priority-setting in research may heavily
depend on the neighborhood association.
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